Hongmei Mo

12.9k total citations · 3 hit papers
157 papers, 7.0k citations indexed

About

Hongmei Mo is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Hongmei Mo has authored 157 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hepatology, 92 papers in Epidemiology and 72 papers in Infectious Diseases. Recurrent topics in Hongmei Mo's work include Hepatitis C virus research (107 papers), Hepatitis B Virus Studies (77 papers) and HIV/AIDS drug development and treatment (69 papers). Hongmei Mo is often cited by papers focused on Hepatitis C virus research (107 papers), Hepatitis B Virus Studies (77 papers) and HIV/AIDS drug development and treatment (69 papers). Hongmei Mo collaborates with scholars based in United States, China and France. Hongmei Mo's co-authors include David D. Ho, Tuofu Zhu, Yunzhen Cao, Richard A. Koup, Ning Wang, John G. McHutchison, Diana M. Brainard, Dale J. Kempf, Evguenia S. Svarovskaia and Akhteruzzaman Molla and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Hongmei Mo

150 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genotypic and Phenotypic Characterization of HIV-1 Patients with Primary Infection

1993 1.0k citations Hongmei Mo, David D. Ho et al. profile →
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1996 601 citations Akhteruzzaman Molla, Marina Korneyeva et al. Nature Medicine profile →
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

2013 438 citations Eric Lawitz, Phillip S. Pang et al. profile →

Peers

Hongmei Mo

HEPAT

EPIDE

VIROL

Lieven Stuyver Belgium

Jacob Lalezari United States

Evguenia S. Svarovskaia United States

Tara L. Kieffer United States

Richard J. Colonno United States

Phillip A. Furman United States

Akhteruzzaman Molla United States

Sandra De Meyer United States

Ann D. Kwong United States

Eoin Coakley United States

Lieven Stuyver Belgium

Hongmei Mo

4.9k ×1.3

HEPAT

3.6k ×1.0

5.0k ×1.5

EPIDE

2.7k ×1.0

VIROL

1.2k ×1.6

Citations per year, relative to Hongmei Mo Hongmei Mo (= 1×) peers Lieven Stuyver

Countries citing papers authored by Hongmei Mo

Since Specialization

Citations

This map shows the geographic impact of Hongmei Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongmei Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongmei Mo more than expected).

Fields of papers citing papers by Hongmei Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongmei Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongmei Mo. The network helps show where Hongmei Mo may publish in the future.

Co-authorship network of co-authors of Hongmei Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Hongmei Mo. A scholar is included among the top collaborators of Hongmei Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongmei Mo. Hongmei Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buuren, Nicholas van, Ricardo Ramírez, Cameron M. Soulette, et al.. (2022). Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B. JHEP Reports. 4(4). 100449–100449. 37 indexed citations

Pitts, Jared, Jiani Li, Jason K. Perry, et al.. (2022). Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Antimicrobial Agents and Chemotherapy. 66(6). e0022222–e0022222. 48 indexed citations

Liu, Yang, Silvia Chang, David Hsieh, et al.. (2021). Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds. Journal of Virological Methods. 292. 114117–114117. 2 indexed citations

Va, Isakov, Charlotte Hedskog, Joel O. Wertheim, et al.. (2021). Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. International Journal of Infectious Diseases. 113. 36–42. 6 indexed citations

Martin, Ross, Jiani Li, Jason K. Perry, et al.. (2021). Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Antiviral Research. 188. 105033–105033. 31 indexed citations

Han, Bin, Hongmei Mo, Evguenia S. Svarovskaia, & Roberto Mateo. (2021). A primary human hepatocyte/hepatic stellate cell co-culture system for improved in vitro HBV replication. Virology. 559. 40–45. 4 indexed citations

Tang, Huamei, Tong Ou, Wei Wu, et al.. (2020). Development of a novel prognostic signature for predicting the overall survival of bladder cancer patients. Bioscience Reports. 40(6). 5 indexed citations

Chaturvedi, Nimisha, Evguenia S. Svarovskaia, Hongmei Mo, et al.. (2019). Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. eLife. 8. 11 indexed citations

Uchida, Yoshihito, Shugo Nakamura, Kayoko Naiki, et al.. (2018). Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Scientific Reports. 8(1). 8818–8818. 11 indexed citations

10.

Ku, Karin S., Ramakrishna K. Chodavarapu, Ross Martin, et al.. (2016). Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. Journal of Clinical Microbiology. 54(7). 1835–1841. 7 indexed citations

11.

Kao, Jia‐Horng, Rong‐Nan Chien, Ting‐Tsung Chang, et al.. (2016). A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver International. 36(8). 1101–1107. 22 indexed citations

12.

Chuang, Wan‐Long, Rong‐Nan Chien, Cheng‐Yuan Peng, et al.. (2016). Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Journal of Gastroenterology and Hepatology. 31(7). 1323–1329. 22 indexed citations

13.

Sarrazin, Christoph, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, et al.. (2016). Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology. 151(3). 501–512.e1. 163 indexed citations

14.

Svarovskaia, Evguenia, Hadas Dvory‐Sobol, Viktoria Gontcharova, et al.. (2013). 1221 NO S282T MUTATION DETECTED BY DEEP SEQUENCING IN A LARGE NUMBER OF HCV PATIENTS WHO RECEIVED GS-7977 WITH RBV AND/OR GS-0938: THE QUANTUM STUDY. Journal of Hepatology. 58. S496–S496. 4 indexed citations

15.

Li, Xinxin, Hongmei Mo, Lihua Zhang, et al.. (2012). Gastroprotective Effects of Ascaridole on Gastric Ulcer in Rats. Chinese Herbal Medicines. 4(1). 58–62. 1 indexed citations

16.

Cheng, Guofeng, Rudolf K. Beran, Huiling Yang, et al.. (2011). An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture. Virology. 422(2). 224–234. 10 indexed citations

17.

Bae, Andrew, Xiaole Qi, Jeanette Harris, et al.. (2010). Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates. Journal of Viral Hepatitis. 18(12). 861–870. 11 indexed citations

18.

Larson, Daniel P., Rolf Wagner, Todd W. Rockway, et al.. (2007). Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(2). 568–570. 16 indexed citations

19.

Mo, Hongmei, Alex K. Konstantinidis, Kent D. Stewart, et al.. (2004). Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology. 329(2). 319–327. 38 indexed citations

20.

Molla, Akhteruzzaman, Marina Korneyeva, Qing Gao, et al.. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine. 2(7). 760–766. 601 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact